Palbociclib Improves Survival in Women with Breast Cancer

Palbociclib (Brand Ibrance) is a targeted therapy (CDK 4/6 inhibitor) manufactured by Pfizer which is used for the treatment of HER2-negative and HR-positive breast cancer. Ibrance is marketed by Pfizer in India under the Brand name of PALBACE.

Source: https://shorturl.at/rxJV7

#Palbociclib #BreastCancer #cancertreatment #SurvivalRates #medicalresearch #HealthCare #Oncology #WomenHealth #CancerTherapy #clinicaltrials